Signatures of non-small cell lung cancer in patients identified using Freenome’s multiomics platform
SOUTH SAN FRANCISCO, April 13, 2022 — Freenome, a privately held biotech company, announced its co-authorship of a study with Merck KGaA, Darmstadt Germany, a leading science and technology company. The companies presented data at the American Association for Cancer Research (AACR) Annual Meeting that demonstrated the combination of multiomics profiling of plasma and computational modeling may be useful in interrogating tumor and non-tumor derived signals for patients with non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer-associated deaths in the United States. The discovery, development and validation of liquid biopsy based clinical biomarkers help support early detection, monitoring and intervention in NSCLC patients.
Freenome’s platform combines the systematic and comprehensive interrogation of both tumor and non-tumor signals with computational biology and machine learning to detect complex patterns of disease using a routine blood draw.
The study investigated the potential of plasma-derived cell-free DNA (cfDNA) and circulating proteins as biomarkers of disease prognosis in a cohort of treatment-naive ALK/EGFR wild type patients with late-stage non-small cell lung cancer (NSCLC).
“This research provides even more insights on how to leverage our platform to develop more personal risk stratification to streamline patient care pathways,” said Mike Nolan, CEO of Freenome.